Trial Profile
The Efficacy of Peg-interferon alfa-2a in HBeAg (+) Chronic Hepatitis B Patients Who Have Been Treated by Entecavir for 48 Weeks But Without HBeAg Loss
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Entecavir
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms Zhangyufeng
- 21 May 2012 New trial record